BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax, formally known as ABT-199, a potent and selective inhibitor of BCL2, gained FDA approval in 2016 for patients with chromosome 17 p deleted Chronic Lymphocytic Leukaemia (CLL).